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Autologous Peripheral Blood Hematopoietic Cell Transplantation
in Dogs with T-Cell Lymphoma
E.E. Warry, J.L. Willcox, and S.E. Suter
Background: Peripheral blood hematopoietic cell transplantation (PBHCT) is a feasible treatment option for dogs with
B-cell lymphoma.
Objective: To examine apheresis and PBHCT outcomes in dogs diagnosed with T-cell lymphoma (TCL).
Animals: Fifteen client-owned dogs diagnosed with high-grade TCL.
Methods: After high-dose cyclophosphamide and rhG-colony-stimulating (rhG-CSF) factor treatment, peripheral blood
mononuclear cells were collected using cell separators. The harvested cells then were infused after varying doses of total
body irradiation (TBI). Postirradiation adverse effects were managed symptomatically and dogs were discharged upon evi-
dence of hematopoietic engraftment.
Results: More than 2 9 106 CD34+ cells/kg were harvested from 15/15 dogs. Thirteen of 15 (87%) dogs engrafted
appropriately, whereas 2 (13%) of the dogs died in the hospital. One dog developed cutaneous B-cell lymphoma 120 days
post-PBHCT. The median disease-free interval and overall survival (OS) of the 13 dogs transplanted in first remission from
the time of PBHCT were 184 and 240 days, respectively. Stage and substage of disease at diagnosis had no effect on OS.
Two of 13 (15%) dogs were alive 741 and 772 days post-PBHCT.
Conclusions and Clinical Importance: PBHCT may be considered as a treatment option for dogs with TCL.
Key words: Apheresis; Bone marrow transplantation; CD34+; Engraftment; Total body irradiation.
T-cell lymphoma (TCL) accounts for approximately10-38% of canine non-Hodgkin’s lymphoma
(LSA).1,2 The disease is considered to have a more
aggressive clinical course and is associated with a poorer
prognosis (6–9 months median survival) when com-
pared to B-cell lymphoma (BCL; 12–14 months median
survival).3
Treatment of all LSA phenotypes historically has
involved the administration of multiagent CHOP-
based (cyclophosphamide, doxorubicin, vincristine,
prednisone) chemotherapy protocols of varying
length.4,5 In addition, the use of cranial and caudal
half-body irradiation in conjunction with chemother-
apy has been described for the treatment of both B-
and T-cell LSA.6,7 In a recent study, 31% of veterinar-
ians treated dogs with TCL using alternative front-line
protocols by including lomustine, procarbazine, and
mechlorethamine while discontinuing the use of doxo-
rubicin and cyclophosphamide.8 However, despite
these different treatment regimens, complete remission
rates and overall survival have remained relatively
unchanged over the last decade.9
Autologous peripheral blood hematopoietic cell
transplantation (PBHCT) after high-dose cyclophos-
phamide and lethal total body irradiation (TBI) for
the treatment of canine B-cell LSA (BCL) has been
reported.10 The median overall survival time for dogs
transplanted before they relapsed was 531 days, with
33% of the dogs still alive >2 years after PBHCT. In
addition, a TerumoBCT (formally CaridianBCT)a cell
separator was able to collect a higher number of both
total CD34+ cells and CD34+ cells/kg when compared
to a Baxter-Fenwal CS-3000 Plusb cell separator. There-
fore, we reasoned that apheresis using a TerumoBCT
cell separator and autologous PBHCT represent a feasi-
ble treatment alternative for dogs with TCL.
In this study, we report the apheresis product analy-
sis, toxicities, and treatment outcome of dogs
diagnosed with TCL treated with an aggressive
myeloablative protocol including high-dose cyclophos-
phamide (HDC), mononuclear cell apheresis, and total
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G-CSF granuloctye colony-stimulating factor
HCT hematocrit
HDC high-dose cyclophosphamide
LRS lactated Ringer’s solution
LSA lymphoma
PARR polymerase chain reaction for antigen receptor
rearrangements
PBHCT peripheral blood hematopoietic cell transplantation
PBMC peripheral blood mononuclear cells
SHC sterile hemorrhagic cystitis
TBI total body irradiation
TCL T-cell lymphoma
WBC white blood cells
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Between November 2008 and March 2012, 15 dogs definitively
diagnosed with high-grade TCL were enrolled. Dogs in a first
and second clinical remission (CR), and 1 dog not in CR, were
included. All clients signed a written informed consent form
approved by the North Carolina State University (NCSU) Veteri-
nary Health Complex Hospital Board.
Donor Preparation for PBMC Apheresis
Donor preparation, including administration of HDCc and
rhG-CSF,d was carried out as previously described.10 All dogs
received IV HDC and mesnae at 500 (5 dogs), 600 (1 dog), 650
(7 dogs), 700 (1 dog), or 750 (1 dog) mg/m2. In some dogs, gluta-
minef (30 mg/kg PO q12h) also was administered.
PBMC Apheresis
PBMC aphereses were performed as previously described,10
using either a Baxter-Fenwal CS-3000 Plus (1 dog) or
TerumoBCT (formally CaridianBCT) (14 dogs) cell separator
machine. In 4 dogs weighing <15 kg, the TerumoBCT cell
separator was primed to ensure hemodynamic stability during the
initial period of apheresis. Three of these dogs have been previ-
ously described.11 The priming solution used in the remaining
dog (6.7 kg) was 100 mL autologous whole blood and 100 mL
0.9% NaCl. In addition, the rinse back products (purged
machine contents after completion of apheresis) in these cases
were collected into an empty bag rather than being returned to
the dogs. This blood (approximately 400 mL) was subsequently
infused into the dogs at approximately 50 mL/h beginning
immediately after the aphereses were completed.
Apheresis Product Analysis
Midprocedure and final harvest products were evaluated as
previously described.10 Polymerase chain reaction for antigen
receptor rearrangements (PARR)12 analysis was used to detect
tumor cell contamination in the 14 dogs with PARR-positive
tumors at diagnosis. When the apheresis product contained
>1 9 107 CD34+ cells/kg, one-half of the product was centri-
fuged to remove the plasma, and the cells were diluted 1:1 in
freezing media containing 20% autologous plasma, 20% Normo-
sol, and 10% dimethyl sulfoxide,g placed in a freezing press,h and
frozen to 80°C in a controlled rate freezing chamber.13 The
remaining apheresis product was refrigerated at 4°C until trans-
plantation.
Mononuclear Cell Product Yield and Collection
Efficiency Calculations
Mononuclear cell product yield, CD34+ cells/kg, and mononu-
clear cells collection efficiencies (MCCE) were calculated as previ-
ously described.10
Total Body Irradiation
The day after apheresis, 14 dogs received TBI at a dose rate
of 7 cGy/min administered with 6 MV photons from a Varian
Clinac 1800,i as previously described.10 In these dogs, TBI con-
sisting of either two 5 Gy fractions at least 3 hours apart (10 Gy,
3 dogs), two 4 Gy fractions at least 3 hours apart on day 1, and
a single 3 Gy fraction on day 2 (11 Gy, 9 dogs), or two 3 Gy
fractions at least 3 hours apart on 2 consecutive days (12 Gy, 1
dog). In 1 dog, two 4 Gy fractions at least 3 hours apart were
given on day 1 and the machine faulted on day 2 after the dog
received approximately 38% of a final 3 Gy fraction (target total
dose of 11 Gy). Therefore, because of the 1-day delay, another
4 Gy dose was administered the next day after the machine was
repaired, for a total of 12 Gy. One dog received TBI at a dose
rate of 10 cGy/min administered with 6 MV photons from a Var-
ian Clinac 21EXj with the dose prescribed to the 100% isodose
line as previously described,10 although a dose miscalculation
resulted in this dog receiving only 8 Gy (of a prescribed 11 Gy
dose) over 3 days. This dog received another 6 Gy (two 3 Gy
fractions at least 3 hours apart) approximately 93 days after the
initial PBHCT. TBI was considered day 0. Immediately after
TBI, the apheresis product was warmed to room temperature
and administered IV over a period of 1 hour.
Post-PBHCT Care
Post-PBHCT care was essentially as previously described.10
Toxicities are described using the Veterinary Co-operative Oncol-
ogy Group v1.1 common terminology criteria for adverse
events.14 In the event of relapse after PBHCT, the dogs received
a variety of chemotherapy protocols at the discretion of the local
veterinarian.
Statistical Analysis
All apheresis data were normally distributed as determined by
a D’Agostino and Pearson omnibus K2 normality test and
Kolmogorov–Smirnov normality test. A Welch’s unpaired t-test
was used to calculate significant differences between the dogs in
this study (Group 1) and 16 dogs from a previous study diag-
nosed with BCL that underwent apheresis using a TerumoBCT
cell separator and PBHCT (Group 2).10 The relationship between
preapheresis parameters, collected CD34+ cells, and MCCE in
both groups was estimated by linear regression and correlation
analysis. One dog that underwent apheresis using a Baxter-Fen-
wal CS-3000 Plus cell separator was not included in the analyses
for Tables 2 and 3. Disease-free interval (DFI), defined as the
time from PBHCT until the time of relapse, and overall survival
(OS), defined as the time from PBHCT until death, were calcu-
lated using the Kaplan–Meier method. For comparison to histor-
ical data, OS also was calculated from the time of diagnosis until
death. DFI and OS were compared between the groups using the
log rank test. Two dogs that died from treatment-related causes
were censored from the DFI analysis but included in the overall
survival analysis.10 Because only 2 dogs had not maintained their
first remission before PBHCT, remission status before PBHCT
was not considered in this analysis. All statistics were calculated
using GraphPad.j A P-value ≤.05 was considered significant.
Results
Patient Characteristics
Fifteen dogs, representing 12 breeds, met the inclu-
sion criteria (Table 1). T-cell phenotype was confirmed
using immunohistochemistry (3 dogs), flow cytometry
(1 dog), or PARR (11 dogs), and the preponderance of
large, immature lymphoblasts with a moderate to high
mitotic rate was used to classify the malignancies as
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high-grade. Four of these dogs were hypercalcemic at
diagnosis, and 3 dogs had a mediastinal mass (2 dogs
had both a mediastinal mass and hypercalcemia).
Eight dogs had stage 5 disease, 3 dogs had stage 4 dis-
ease, and 4 dogs had stage 3 disease. Nine dogs were
substage a, whereas 6 dogs were substage b (5/6 sub-
stage b dogs had stage 5 disease). One dog was in sec-
ond remission before PBHCT, whereas 1 dog was not
in CR upon arrival at NCSU.
Toxicity
Acute HDC Toxicity. Seven of 15 (47%) dogs (1 at
500 mg/m2, 1 at 600 mg/m2, 3 at 650 mg/m2, 1 at
700 mg/m2, and 1 at 750 mg/m2) were reported to
have experienced an adverse event. One dog experi-
enced grade-2 lethargy and inappetence only, whereas
6 dogs developed grade-4 neutropenia. Of the 6 neu-
tropenic dogs, 3 also developed grade-3 thrombocyto-
penia, 3 became febrile, and 3 exhibited grade-2
gastrointestinal (GI) signs. Four of these dogs were
hospitalized and given supportive care, including fluid
administration, antibiotics, and antiemetics. Within
24 hours of hospitalization, all 4 dogs were discharged
and cytopenias resolved within 7 days. Only 1 dog
(650 mg/m2 HDC) exhibited clinical signs consistent
with sterile hemorrhagic cystitis (SHC) and this dog
eventually required surgery to repair a ruptured uri-
nary bladder, presumably secondary to severe SHC
(moderate to marked transmural necrotizing cystisis).
Regardless of the severity of HDC toxicities, all dogs
recovered and were able to proceed with rhG-CSF
treatment and PBMC apheresis.
Acute TBI Hematologic Toxicity. All dogs developed
grade-4 neutropenia and thrombocytopenia as previ-
ously described.10 Grade-4 neutropenia (<500/lL)
lasted from 3 to 11 days (median, 6 days) whereas
grade-4 thrombocytopenia (<25 9 103/lL) persisted
for 0–21 days (median, 8 days), with 8 (53%) dogs hav-
ing grade-4 thrombocytopenia at discharge. No statisti-
cally significant difference in either duration or grade
of neutropenia and thrombocytopenia was observed
between dogs that received 10 Gy or 11 Gy of irradia-
tion (P = .583). Nine of 15 (60%) dogs experienced
grade-2 petechiation, ecchymosis, or both, 1 (7%) dog
developed hematuria, and 1 (7%) dog developed epi-
staxis. Fifteen (100%) dogs received irradiated15
(20 Gy) blood products which included DEA 1.1-nega-
tive fresh whole blood, donor-matched fresh whole
blood, frozen platelet concentrate, donor-matched
packed red blood cells, and fresh platelet concentrate.
There was no statistically significant difference in the
median duration of hospitalization for dogs receiving
10 Gy of TBI (median, 18 days; range, 14–23 days)
when compared to dogs receiving 11 Gy of TBI (med-
ian, 22.5 days; range, 17–34 days; P = .1874).
Acute TBI Gastrointestinal Toxicity. Fourteen of 15
(93%) dogs experienced GI adverse events, including
vomiting, diarrhea, inappetence, or some combination
of these. Six (40%) dogs vomited during their hospital-
ization (3 grade-2, 3 grade-3). Eleven (73%) dogs also
developed diarrhea (3 grade-1, 4 grade-2, 4 grade-3).
Inappetence developed in 10 (67%) dogs for a variable
amount of time (3 grade-1, 2 grade-2, 3 grade-3, 2
grade-4). Three (20%) dogs also received nutritional
support including partial parental nutrition (1), total
parental nutrition (1), or a combination of partial
parental nutrition and amino acid supplementation (1).
Chronic TBI Toxicity. One (7%) dog developed
multiple SC nodules 120 days post-PBHCT that were
diagnosed as cutaneous B-cell LSA by flow cytometry.
This dog continued to develop additional SC nodules
despite receiving a variety of chemotherapeutic agents
and local irradiation, and was euthanized because of
progressive B-cell LSA 605 days post-PBHCT.
TBI-Related Mortality. Two (13%) dogs died
shortly after PBHCT. One dog that received 11 Gy
TBI (two 4 Gy fractions at least 3 hours apart on day
1, and a single 3 Gy fraction on day 2) died of clinical
signs consistent with sepsis 13 days post-PBHCT. One
dog, that was not in remission upon arrival at NSCU,
received doxorubicink (40 mg/m2 IV) and melphalanl
(30 mg/m2 PO) followed by rhG-CSF (5 lg/kg SC)
and plerixaform (240 lg/kg SC) 1 week later. After
apheresis and 12 Gy TBI (two 3 Gy fractions at least
3 hours apart on 2 consecutive days), the dog died of
clinical signs consistent with severe GI toxicity 4 days
post-PBHCT.
Apheresis
Effects of rhG-CSF Treatment. As reported previ-
ously,10 no signs of adverse effects were seen in any
dogs receiving rhG-CSF before apheresis. In all dogs,
preapheresis WBC (mean, 45,340  15,963 cells/lL)
Table 1. T-cell lymphoma case details before
PBHCT.
Signalment
Number of dogs 15
Breeds 12 (2 Box, 2 GR, 2 LR)
Age (months) Mean, 63.6 (range, 36–108)
Spay/neuter 9NM, 1IM, 4SF, 1IF
Weight (kg) Mean, 28.4 (range, 6.7–54.4)








Relapse before PBHCT 1
Remission before PBHCT 14
Days from dx to PBHCT Mean 121 (range, 61–217)
PARR + tumors 14
Box, Boxer; GR, Golden Retriever; LR, Labrador Retriever;
NM, neutered male; IM, intact male; SF, spayed female; IF,
intact female; LN FNA, lymph node fine needle aspirate;
PBHCT, peripheral blood hematopoietic cell transplantation;
PARR, PCR for antigen receptor rearrangements.
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and mononuclear cell counts (mean, 3,181  1,872
cells/lL) were much higher than our hospital’s normal
reference range (WBC reference interval, 4,390–
11,610 cells/lL; mean, 8,000 cells/lL; monocyte refer-
ence interval, 75–850 cells/lL; mean, 462 cells/lL;
Table 2). There was no statistically significant differ-
ence when comparing these dogs to a previous report
of 16 dogs with BCL harvested using a TerumoBCT
cell separator10 with respect to preapheresis WBC
count (P = .1761) and monocyte count (P = .0623).
All rhG-CSF-treated dogs underwent apheresis.
Apheresis Procedure. All 15 dogs completed the
apheresis. There was no statistically significant differ-
ence when comparing these dogs to a previous report
of 16 dogs with BCL harvested using a TerumoBCT
cell separator10 with respect to collection duration
(P = .7365), total blood volume processed (P = .7563),
postapheresis monocyte count (P = .0636), and Hct
(P = .1954; Table 2). There was a statistically signifi-
cant difference when comparing postapheresis WBC
counts (P = .0442) and the amount of ACD-A infused
during the procedure (P = .0262).
Effects of Apheresis. Fourteen of 15 dogs tolerated
the procedure. One dog developed clinically relevant
bleeding from the jugular catheter site during the last
15 minutes of the procedure. The dog’s platelet count
(preapheresis, 177 9 103 cells/lL; postapheresis,
30 9 103 cells/lL) and hematocrit (preapheresis, 45%;
postapheresis 20%) decreased substantially during the
procedure. A coagulation panel immediately postaph-
eresis was abnormal (PT, no clot after 40 s; PTT, no
clot formation after 120 s; d-dimer, >2,000 ng/mL). A
coagulation panel the next day was normal (PT, 8.1 s;
PTT 13 s, d-dimer <250 ng/mL) except for grade-4
thrombocytopenia (26 9 103 cells/lL), although all
signs of bleeding slowly resolved during the day with-
out medical management. One dog experienced mild
generalized urticaria immediately after the procedure
that responded appropriately to diphenhydramine
administration. For the 4 dogs weighing <15 kg,
machine priming with a variety of fluids was sufficient
to maintain cardiovascular stability and the aphereses
were completed uneventfully.
Apheresis Cell Yield. Table 3 compares the apheresis
products of these dogs with a previous report of 16
dogs with BCL harvested using a TerumoBCT cell sep-
arator.10 There were no statistically significant differ-
ences when comparing the mean WBC (P = .6836),
red blood cells (P = .4089), or mononuclear cells
(P = .8369) harvested. In addition, we found no statis-
tically significant difference in the number of CD34+
cells/kg harvested (P = .3690) and the cell separator
MCCE (P = .7643) between the 2 groups. There was a
statistically significant difference when comparing the
mean number of platelets (P = .0422) harvested.
PARR analysis was negative in 13/14 harvests for
which the original tumor was PARR-positive. The one
dog with a PARR-positive harvest also had PARR-
positive blood at presentation to NCSU. Two other
dogs with PARR-positive blood at presentation to
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Factors Affecting Apheresis Yield. We examined the
effect of preapheresis Hct on the machine MCCE
because we reported previously that preapheresis Hct
was moderately correlated (R2 = 0.3371, P = .0184)
with increased MCCE in dogs with BCL.10 In the
TCL dogs, this correlation was not evident
(R2 = 0.1280, P = .2091; Fig 1A). When combining
these data from both groups of dogs (n = 30), how-
ever, preapheresis Hct was correlated (R2 = 0.2021,
P = .0127) with machine MCCE (Fig 1B). Concor-
dant with previous results,10 preapheresis leukocyte
counts did not affect the machine MCCE
(R2 = 0.01627, P = .6639) or the number of CD34+
cells/kg (R2 = 0.05644, P = .4135; data not shown).
Finally, concordant with previous results,10 preapher-
esis monocyte count was not significantly correlated
with the number of CD34+ cells/kg harvested
(R2 = 0.00385, P = .9516; Fig 1C), although when
combining the 2 groups of dogs there was a
significant correlation (R2 = 0.2119, P = .0105;
Fig 1D).
PBHCT Outcome
Platelet Recovery. We examined the effects of the
number of transplanted CD34+ cells/kg on platelet
recovery at day +14 after PBHCT. Contrary to previ-
ous findings,10 there was no statistically significant
difference (P = .1983) in platelet counts at discharge in
dogs receiving <6 9 106 CD34+ cells/kg (mean,
43,000  57,000/lL) compared with dogs receiving
≥6 9 106 CD34+ cells/kg (mean, 119,000  123,000/
lL), although only 3/4 dogs that received <6 9 106
CD34+ cells/kg were included in this analysis (1 dog
died in the hospital). When we combined these data
with the previously reported BCL dogs, the difference
in day +14 platelet counts became significant
(P = .0234). There was no statistically significant
difference in day +14 platelet counts when examining
TCL dogs that received <1 9 107 CD34+ cells/kg
versus >1 9 107 cells/kg alone or when combining
these data with the previously reported BCL dogs.
Remission Duration. The median DFI for the 13
dogs that did not relapse before PBHCT and were
in CR at the time of PBHCT from the time of
PBHCT to relapse was 184 days (range, 28–738 days;
Fig 2A). Three (23%) of these 13 dogs relapsed
within 4 months of PBHCT, 3 (23%) dogs relapsed
between 4 and 8 months after PBHCT, 5 (38%)
dogs relapsed after 8 months of PBHCT (at 8.3, 10,
12.9, 18.3, and 24.6 months), and 1 (8%) dog had
not relapsed after 24.7 months. There was no statisti-
cally significant difference (P = .7665) in DFI
between dogs that received 10 or 11 Gy TBI. When
we compared the median DFI between the dogs with
TCL in this study and the previously reported BCL
dogs,10 there was no statistically significant difference
(P = .0704) between the 2 groups (184 days versus
511 days, respectively; Fig 2B). One dog that had
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remained disease-free for 78 days, whereas 1 dog not
in clinical remission on presentation at NCSU died
in the hospital.
Overall Survival. The median OS for the 13 dogs
that were in CR at the time of PBHCT from the time
of PBHCT was 239.5 days (range, 4–738 days;
A B
C D
Fig 2. (A) Disease-free interval of TCL and (B) TCL and BCL10 (P = .0704) cases combined. (C) Overall survival of TCL and (D)
TCL and BCL10 (P = .0551) cases combined.
A B
C D
Fig 1. Correlation between preapheresis blood cell parameters and harvest outcomes. (A) Linear regression analysis did not show a cor-
relation in TCL dogs between preapheresis Hct and MCCE (R2 = 0.1280, P = .2091) or (C) preapheresis mononuclear cell counts and
the number of CD34+ cells/kg harvested (R2 = 0.00385, P = .9516). (B) Linear regression analysis did show a correlation between pre-
apheresis Hct and MCCE (R2 = 0.2021, P = .0127) and (D) preapheresis mononuclear cell counts and the number of CD34+ cells/kg
harvested (R2 = 0.2119, P = .0105) when TCL and BCL10 cases were combined.
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Fig 2C). When we compared the median OS between
the dogs with TCL in this study and the previously
reported BCL dogs,10 there was no statistically signifi-
cant difference (P = .0551) between the 2 groups
(240 days versus 531 days, respectively; Fig 2D). The
median OS from the time of diagnosis to death of the
13 TCL dogs in CR at the time of PBHCT was
602 days (range, 246–928 days), with 2 (14%) dogs
still alive at 741 and 772 days. Stage and substage of
disease at diagnosis had no effect on OS (P = .5862
and P = .1303, respectively).
Discussion
Similar to our previous study using PBHCT to treat
dogs with BCL,10 an adequate number of peripheral
blood CD34+ cells could be harvested using a Ter-
umoBCT cell separator for HCT after myeloablative
treatment. In addition, the majority of dogs tolerated
the toxicities associated with escalating doses of HDC
and TBI and achieved complete hematologic reconsti-
tution after transplantation.
In an effort to decrease the potential for minimal
residual disease in the blood of the affected dogs,
HDC dose intensification was incrementally increased
throughout the study. As such, 9 dogs received
≥650 mg/m2 of cyclophosphamide, with 1 dog receiv-
ing 750 mg/m2. Although some dogs developed
grade-4 neutropenia, only 4 dogs required brief hospi-
talization (1 received 500 mg/m2, 1 received 600 mg/
m2, 2 received 650 mg/m2), only 1 dog developed
cyclophosphamide-induced cystitis, and all dogs were
able to proceed with apheresis. These results suggest
that cyclophosphamide can be administered to dogs in
amounts up to 3.75 times the standard dosage if
appropriate protocols are used and supportive care is
given if needed.
In a previous report of PBHCT of dogs with BCL,10
the relapse rate was approximately 65% when 10 Gy of
TBI was used to achieve molecular remission. In this
study, we continued to escalate the dose of TBI because
a higher dose of irradiation should, theoretically, lead
to a better clinical outcome16–18 and because TCL is a
more aggressive disease than BCL. Therefore, we
administered >10 Gy TBI to 12 dogs while incorporat-
ing more fractionated protocols in an effort to decrease
the associated GI toxicities. In addition, many dogs
received enteral glutamine, an antioxidant that may
protect the GI tract from the adverse effects associated
with radiation treatment.19,20 Although 2 dogs in this
study died in the hospital, only 1 dog, that was not in
CR at the time of presentation to NCSU and subse-
quently received high-dose chemotherapy 1 week before
TBI, had evidence of severe GI toxicity at necropsy.
Therefore, we conclude that dogs can routinely tolerate
>10 Gy TBI when administered in multiday fraction-
ated protocols. In future PBHCT studies, we also will
utilize lower dose rates (regardless of overall dose)
because it appears that both radiation dose rate and
overall dose are the most important factors in acute
toxicity of the canine GI tract associated with TBI.16
Overall, there were only minor differences between
the TCL dogs in this study and the BCL dogs in a pre-
vious study10 with respect to apheresis characteristics
and apheresis product counts. When we examined a
variety of factors affecting apheresis cell yield, preaph-
eresis Hct was not significantly correlated with
increased MCCE and preapheresis monocyte count
was not significantly correlated with the number of
CD34+ cells/kg harvested as we found in the BCL
dogs. The lack of correlation between the preapheresis
monocyte count and number of CD34+ cells/kg har-
vested is most likely a reflection of the lower overall
number of monocytes before the procedure in the TCL
dogs, whereas the reason for the lack of correlation
between preapheresis Hct and increased MCCE in
these dogs is not clear. However, when combining the
data from both studies, these correlations again
became significant. Importantly, rhG-CSF administra-
tion was well tolerated and the resultant apheresis
products contained >2 9 106 CD34+ cells/kg (target
cell dose) in all TCL dogs.
When apheresis products contain >1 9 107 CD34+
cells/kg, we routinely cryopreserve one-half of the
product in the event a dog relapses and the owners
want to perform a second PBHCT. The cryopreserved
product was given to 1 dog that relapsed approxi-
mately 93 days after PBHCT after additional chemo-
therapy (doxorubicin [30 mg/m2] and melphalan
[30 mg/m2]) and TBI (6 Gy). Complete hematologic
reconstitution was again achieved, and the dog
remained in clinical and molecular remission for an
additional 225 days. This case underscores the utility
of apheresis product cryopreservation and corrobo-
rates data from humans showing the feasibility of sec-
ond hematopoietic cell transplants in patients relapsing
after prior PBHCT.21,22
One dog developed a second cancer after PBHCT.
Interestingly, this dog developed a B-cell malignancy
whereas a dog in a previous report10 with B-cell
lymphoma developed epitheliotropic T-cell lym-
phoma. Late second malignancies after total body
irradiation have been reported in both dogs23 and
humans.24
Two factors that are consistently identified as having
negative prognostic importance in dogs with lym-
phoma are immunophenotype and WHO substage.25,26
Therefore, dogs with a T-cell immunophenotype and
substage b disease tend to have substantially shorter
remission and survival durations. Interestingly, in this
study where 40% of the TCL dogs were WHO sub-
stage b, the median OS, when defined as time from
diagnosis to death, was 602 days, with 2 dogs (1 Stage
3A, 1 Stage 5b) still alive at manuscript preparation.
Factors that may have positively influenced the sur-
vival of the dogs in this study include the higher doses
of HDC and TBI used in the pre-PBHCT conditioning
regimen and the unknown number of dogs with low-
grade tumors27 because a LN biopsy was obtained in
only 3 dogs (all 3 dogs were diagnosed with an aggres-
sive T-cell lymphoma called peripheral T-cell
lymphoma). In addition, because 87% of the dogs
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maintained a first remission (median, 3.7 months;
range, 2–5.8 months) before transplantation, a positive
selection bias in this population may have influenced
our results. Regardless, it appears that PBHCT
achieved a longer OS (602 days) in dogs with TCL
than previously reported studies (159 days3 and
235 days28).
In summary, we show that an adequate number of
peripheral blood CD34+ cells can be routinely har-
vested from dogs with TCL and used for autologous
PBHCT. Based on this small number of dogs, it
appears that, although PBHCT does not lead to a sta-
tistically significant increase in DFI in dogs with TCL,
it can lead to a longer median OS when compared to
historical studies using multiagent chemotherapy regi-
mens. Because 1 dog in this study achieved post-
myeloablative hematopoietic reconstitution after a
second PBHCT using a cryopreserved autologous
apheresis product, we suggest, that, similar to human
protocols,29 cryopreserved canine apheresis products
can be routinely used for both autologous and alloge-
neic PBHCT. Based on an apparent increase in the
median OS of the dogs in this study (with 2 dogs alive
>2 years after diagnosis), PBHCT may be considered
as a viable alternative treatment for dogs with high-
grade TCL.
Footnotes
a TerumoBCT, Lakewood, CO
b Baxter Healthcare Corporation, Deerfield, IL
c Cytoxan, Cyclophosphamide for Injection, USP; Baxter Health-
care Corporation, Deerfield, IL
d Neupogen; Amgen, Thousand Oaks, CA
e Mesnex; Sagent Pharmaceuticals, Schaumburg, IL
f L-glutamine; Vitamin Shoppe, North Bergen, NJ
g DMSO; Amresco, Solon, OH
h Gambro DF-700 Bag Press; ThermoFisher Scientific, Hudson,
NH
i Varian, Palo Alto, CA
j GraphPad Software, San Diego, CA
k Adriamycin; Bedford Laboratories, Bedford, OH
l Alkeran; GlaxoSmithKline, Brentford, London, UK
m Mozobil; Genzyme Corporation, Cambridge, MA
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